Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal

Table 3 Characteristics of patients achieving ≥5-year survival without disease recurrence after systemic therapy plus RFA for liver-only CLM

Patient	Systemic therapy			Clinical features
	Response¹	No. of lines	Regimen(s) administered	Number of CLM	Size²of CLM	CEA level (ng/ml)
1	Partial remission	1	FOLFIRI	1	2.5 cm	12
2	Partial remission	2	FOLFOX, FOLFIRI	1	2.1 cm	23
3	Partial remission	1	FOLFOX	2	2.2 cm	13
4	Partial remission	2	FOLFIRI + Bevacizumab, FOLFOX + Cetuximab	3	3.0 cm	114
5	Partial remission	1	FOLFIRI + Bevacizumab	2	3.1 cm	57
6	Partial remission	1	FOLFOX	1	2.7 cm	4

Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFOX, 5-fluorouracil, leucovorin, oxaliplatin; RFA, radiofrequency ablation.
¹RECIST-defined response to the immediate preceding regimen before RFA treatment. ²after decrease of ≥30% in size following the immediate preceding regimen before RFA treatment.

ISSN: 1471-2407